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CHAPTER 1.  INTRODUCTION 
Atherosclerotic cardiovascular disease (ASCVD) including myocardial infarction 
(MI), ischemic stroke and peripheral artery disease (PAD) remain the leading cause 
of death globally (1,2). Despite major advances in the understanding of the underlying 
disease process of atherosclerosis and identification of several factors associated with 
disease risk, the burden of ASCVD remain high (2).  
Nutrition represent an important area of research for primary prevention of ASCVD 
because biologically relevant dietary exposures in the human diet may have the 
potential to influence disease risk over decades.  
N-3 polyunsaturated fatty acids (PUFAs) are organic compounds, which may affect a
variety of biological processes of relevance to human health (3). The potential health
benefits of n-3 PUFAs found in seafood has been subject to extensive research since
the 1970s where Dyerberg and colleagues from Aalborg hypothesised that long-chain
(LC) marine n-3 PUFAs might protect against atherosclerosis and thrombosis based
on their expeditions to Greenland (4,5). Since then several epidemiological studies in
other populations and some randomized clinical supplementation trials have
supported the hypothesis that LC n-3 PUFAs may lower the risk of coronary heart
disease (CHD) (6–9).
The potential health benefits of the plant-derived n-3 PUFA, alpha-linolenic acid 
(ALA), have been less studied and results in relation to ASCVD have been conflicting 
(10). However, apart from potential beneficial effects of ALA per se, ALA has also 
attracted public health relevance because it has been suggested as an alternative and a 
more sustainable source of LC n-3 PUFAs compared to LC n-3 PUFAs mainly derived 
from fatty fish and/or fish oil supplements (11,12). Also, ALA has been suggested to 
be an important mediator of a protective effect on CHD provided by the 
Mediterranean diet (13–15). 
This thesis aimed to explore the associations between ALA and the risk of developing 
MI, ischemic stroke and PAD using complementary measures of exposure including 
estimated ALA intakes and adipose tissue content of ALA as a biomarker of its intake 
and metabolism. The included papers are based on data from the Danish Diet, Cancer 
and Health (DCH) cohort, which is a cohort of more than 57,000 middle-aged Danish 
men and women.  
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CHAPTER 2. BACKGROUND 
2.1 ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASE 
Atherosclerosis is the main underlying disease process that may result in development 
of ASCVD. The atherosclerotic process begins in early life and may gradually 
progress with age under major influence by genetics, diet and lifestyle (16,17).  
Progression of atherosclerosis and formation of atherosclerotic plaques are complex 
processes that occur in the arterial wall (18,19). In brief, the atherosclerotic process is 
believed to be initiated by endothelial dysfunction, retention of low-density 
lipoprotein (LDL) particles in the sub-endothelial layer and inflammation (18). The 
inflammatory response results in expression of adhesion molecules, chemokines and 
other pro-inflammatory cytokines, which leads to attraction of circulating leukocytes, 
especially monocytes, and mediates their migration and differentiation into 
macrophages in the arterial wall (18,19). The macrophages engulf the trapped and 
minimally modified and oxidized LDL particles and then becomes lipid rich foam 
cells. These lipid-laden foam cells trapped in the sub-endothelial layer continues 
internalization of atherogenic lipoproteins, which may be followed by apoptosis and 
development of a necrotic core within the atherosclerotic plaque (18,19).  
Atherosclerotic plaque growth may over time result in narrowing of the arterial lumen, 
which gradually may limit the blood flow and hereby result in ischemia due to 
insufficient oxygen supply. Stable ASCVD may in the coronary arteries present as 
angina pectoris; or in the peripheral arteries in the legs as muscle discomfort or pain 
that typically is provoked by exercise and relieved by rest. However, atherosclerotic 
plaques may disrupt resulting in thrombus formation and sudden total or partial 
occlusion of the arterial lumen that may lead to acute critical ischemia in the affected 
arterial territory. In the cerebral arteries, acute ischemia may result in a transient 
ischemic attack or an ischemic stroke with rapid onset of focal neurologic dysfunction 
(20), whereas ischemia in the coronary arteries may present with various 
combinations of symptoms such as chest pain or upper extremity, mandibular or 
epigastric discomfort during exertion or at rest (21). In the peripheral arteries, acute 
ischemia mediated by atherothrombosis may present with symptoms as intermittent 
claudication or in later stages severe ischemic rest pain and gangrene (22).  
The majority of cases of PAD and MIs are caused by atherosclerosis, whereas 
ischemic stroke is a more heterogeneous condition, which can be divided into 
subtypes according to the Trial of Org 10172 in Acute Stroke Treatment (TOAST) 
classification system based an assumed etiology (23). The TOAST classification 
system separates ischemic strokes into five groups including large artery 
atherosclerosis, small-vessel occlusion, cardio-embolism, stroke of other etiology and 
stroke of undetermined etiology (23). In the context of atherosclerosis, ischemic 
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strokes due to large artery atherosclerosis and ischemic strokes due to small vessel-
occlusion are most relevant. Ischemic strokes due to large artery atherosclerosis is 
believed to be caused mainly by atherosclerosis within the larger arteries (23), 
whereas ischemic stroke due to small vessel-occlusion may occur as a result of 
atherosclerosis or lipohyalinosis affecting the smaller penetrating arteries (24).  
A lowering of plasma LDL-cholesterol has convincingly been shown to reduce 
atherosclerosis and risk of ASCVD (25,26). Also, the role of inflammation has been 
considered a pivotal pathophysiological component of atherosclerosis for decades and 
is also believed to be important for the stability of atherosclerotic plaques and hence 
the risk of disruption resulting in acute events of ASCVD (27,28). Thus, targeting 
inflammation has been hypothesised as a way to reduce the risk of ASCVD (29). 
Interestingly, a recent clinical trial suggested targeting the pro-inflammatory cytokine 
interleukin-1b with an monoclonal antibody in subjects with a prior MI and elevated 
levels of C-reactive protein was associated with a lower rate of recurrent 
cardiovascular events compared with subjects receiving placebo (30).  
2.2 POLYUNSATURATED FATTY ACIDS 
PUFAs are fatty acids characterized by two or more double bindings in their carbon 
chain and are named according to the number, configuration and position of such 
double bonds (8). PUFAs has traditionally been divided into n-3 and n-6 PUFAs based 
on the position of the first double bond counted from the methyl end of the carbon 
chain (8). These PUFA families each consist of fatty acids with varying carbon chain 
length and degree of unsaturation, which are important for their pathophysiological 
and biological properties.  
The shorter-chain n-3 PUFA ALA (18:3n-3) and the n-6 PUFA linoleic acid (LA, 
18:2n-6) are the most abundant PUFAs in the typical Western diet. ALA is 
synthesized in plants and is found in high concentrations in walnuts and plant oils 
based on canola, soybean and flaxseed (12). However, ALA can also be found in other 
foods such as green leafy vegetables, whole-grain cereals, margarines, mayonnaises, 
dairy products and meat (31–33). LA is the most widely consumed n-6 PUFA found 
in many food sources, but the quantitively most important are plant oils and 
commercially available food products containing such oils, meat and eggs (34). The 
typical intake of PUFAs varies substantially by country, but most Western populations 
consume on average 0.5 to 2.3 g/d of ALA and 10-17 g/d of LA (12,34,35).  
PUFAs may upon ingestion become available for energy production, incorporation 
into cells membranes and pools for storage (e.g. adipose tissue) or conversion into 
longer and more unsaturated fatty acids (12,36). ALA and LA are both considered 
essential fatty acids because humans lack the capacity to insert double bonds in the  
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n-6 and n-3 position necessary for production of these fatty acids endogenously. 
However, ALA and LA are both precursors for longer and more unsaturated fatty 
acids (37). ALA may thus be converted into the longer-chain n-3 PUFAs 
eicosapentaenoic acid (EPA, 20:5n-3), docosapentaenoic acid (DPA, 22:5n-3) and 
docosahexaenoic acid (DHA, 22:6n-3), whereas LA can be converted to arachidonic 
acid (20:4n-6) and fatty acids and beyond (Figure 1) (12,37). 
 
Figure 1. The pathway for synthesis of longer-chain PUFAs.  
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The conversion of ALA and LA into longer-chain fatty acids occurs in a complex 
pathway by shared enzymes, but no interconversions occurs between the two PUFA 
families (Figure 1). The conversion efficiency of ALA into LC n-3 PUFAs appears to 
be very limited in humans with reported conversions of ALA to EPA of less than 10% 
and to DHA of less than 1% (12,37). However, women and especially those of fertile 
age may be more efficient to convert ALA into LC n-3 PUFAs compared to men (38). 
Also, high intakes of LA or LC n-3 PUFAs may inhibit the metabolism of ALA due 
to competitive mechanisms (39–41). Although the conversion efficiency of ALA may 
be limited, the absolute contribution to the endogenous exposure of predominantly 
EPA derived from ALA may be of significance due to a markedly higher intake of 
ALA than LC n-3 PUFAs in most populations. 
PUFAs are biologically active compounds that may affect a myriad of molecular 
pathways such as alteration of physical and chemical properties of cellular membranes 
and direct effects on ion channels, gene expression and biosynthesis of lipid signalling 
molecules and other mediators (8,42). Important lipid signalling molecules not least 
eicosanoids including prostaglandins, thromboxanes and leukotrienes, which are 
involved in regulation of several biological functions important for vascular function, 
thrombosis and inflammatory processes (3,42). Both PUFA families may produce 
inflammatory signaling molecules, but the n-3 PUFAs have been ascribed anti-
inflammatory effects, and the lipid signaling molecules derived from the n-3 PUFAs 
are considered less proinflammatory than those derived from n-6 PUFAs (3). 
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CHAPTER 3. AIMS AND HYPOTHESES 
The objective of this thesis was to investigate the associations between the energy-
adjusted intake of ALA and adipose tissue content of ALA and the rate of MI, 
ischemic stroke and PAD.  
We hypothesized that estimates of ALA exposure were inversely associated with the 
rate of MI, ischemic stroke and PAD.   
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CHAPTER 4. METHODS 
The methods used have been described in detail in the five papers included in this 
thesis and will only be described in brief below.  
 
4.1 STUDY POPULATION 
The studies included in this thesis were based on data from the DCH cohort. The 
cohort was established to investigate diet and lifestyle in relation to development of 
cancer and other chronic diseases (43). The study participants were recruited from in 
and around the two largest cities in Denmark, Copenhagen and Aarhus, by letter 
invitations. The criteria for invitation were as follows (43): 
1. Age between 50 and 64 years 
2. Born in Denmark 
3. No previous diagnosis of cancer registered in the Danish Cancer Registry 
Potentially eligible study participants were retrieved using the Danish Civil 
Registration System and the enrolment began in December 1993 and ended in May 
1997 (43). A total of 160,725 participants including 80,996 men and 79,729 women 
were invited to participate in the study, which corresponded to nearly 20% of the 
Danish population aged 50 to 64 years at the time of invitation. A total of 57,053 
participants (27,178 men and 29,875 women) accepted the invitation (43). A 
randomly drawn sample of 3,500 participants was drawn from the cohort to assess the 
exposure distribution for biomarkers studies of fatty acids.  
Processing delay in the registration of diagnoses of cancer in the Danish Cancer 
Registry resulted in invitation of some participants that had developed cancer. All 
participants registered with a diagnosis of cancer before enrolment were excluded 
from the analyses included in this thesis. Also, participants with a previous diagnosis 
of the relevant outcomes of interest were excluded in order to study the associations 
between ALA exposure in relation to development of ASCVD. In analyses of PAD, 
we additionally excluded participants with a previous diagnosis of chronic kidney 
insufficiency because these patients might develop atypical or more aggressive forms 
of PAD to whom the main results might not be generalised to. Finally, participants 
with missing information on exposures and/or covariates were excluded assuming that 
these were missing at random.  
All participants gave written informed consent at inclusion, and the study was 
approved by the relevant Ethic Committees and the Data Protection Agency.  
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4.2 ASSESSMENT OF DIETARY INTAKE OF ALA 
All participants received a 192-item food frequency questionnaire (FFQ) by mail and 
was asked to report their average intake the past year of foods and beverages within 
12 possible response categories ranging from never to 8 times or more per day (43). 
The FFQs were optically scanned and checked for missing values and uncertainties 
and clarified by technicians at a physical examination performed at two study centres 
(43). The daily intake of ALA and other nutrients were estimated for each participant 
using the software program FoodCalc based on standardized recipes and portion sizes. 
The FFQ was developed during the planning of the DCH cohort (44) and has 
previously been validated against two times 7-day weighted diet records and found 
suitable to categorise subjects according to their intake of energy and PUFAs (45).  
 
4.3 ASESSMENT OF ADIPOSE TISSUE CONTENT OF ALA 
All participants were asked to have a subcutaneous adipose tissue biopsy taken from 
the buttocks during the physical examination. The adipose tissue biopsies were 
collected using a Luer-lock system consisting of a needle, a venoject multi-sample 
Luer adapter and an evacuated blood tube according to the method of Beynen and 
Katan (46). Samples were stored in liquid nitrogen vapour until analysis. The fatty 
acid composition of adipose tissue was determined by gas chromatography and 
expressed as area percentage of total fatty acids. The method used for fatty acid 
analysis has previously been described in detail in the individual papers included in 
the thesis and elsewhere (47).  
 
4.4 ASSESSMENT OF COVARIATES 
All participants were asked to fill in a questionnaire during the physical examination 
on social and lifestyle factors such as length of schooling, smoking habits and 
physical activity. Also information on hypercholesterolemia, hypertension or 
diabetes mellitus and relevant medications used to treat these conditions were 
collected (43). The questionnaires were checked for reading errors and missing 
information by technicians who also performed anthropometric measurements such 
as height, weight and waist circumference of the participants (43). Information on 
alcohol intake and dietary covariates was derived from the FFQ. Information of a 
history of atrial fibrillation/flutter and history of chronic kidney insufficiency prior 
to baseline was not collected during the recruitment process. Instead, history on 
atrial fibrillation/flutter (International Classification of Diseases 8th revision (ICD-
8): 42793, 42794 & ICD-10: DI48) and chronic kidney insufficiency (ICD-8: 79299 
& ICD-10: DN18, DN181, DN182, DN183, DN184; DN185, DN188 and DN189) 
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was obtained by record linkage with the nationwide Danish National Patient 
Register (DNPR).  
 
4.5 OUTCOME ASSESSMENT 
The case ascertainment in the presented papers was based on record linkage between 
the cohort participants and discharge diagnoses registered in the DNPR. This 
administrative register was established in 1977 and has gradually been expanded 
with more information over the years (48,49). Initially, the DNPR covered all 
inpatient contacts to Danish hospitals, but from 1995 and onwards all outpatient 
activities and emergency room contacts were included as well. Primary and 
secondary discharge diagnoses were classified in the DNPR according to the ICD-8 
until the end of 1993, and according to the ICD-10 from then (49). 
 
Myocardial infarction 
Participants registered with a primary or secondary discharge diagnosis of MI (ICD-
8: 410-410.99, or ICD-10: DI210–DI219) or cardiac arrest (ICD-8: 427.27 or ICD-10: 
DI460–DI469) registered in the DNPR or the Danish Causes of Death Registry (50) 
until July 2013 were identified (51). All potential cases identified from baseline 
through 2003 were validated by review of medical records. All cases of cardiac 
arrest were included as cases if the arrest was considered to be of cardiac origin after 
validation. From January 2004 and onwards all participants registered with a 
diagnosis of MI from a hospital ward was accepted as cases, because the positive 
predictive value of a diagnosis of MI was shown to be above 92% after validation of 
more than 800 of the first registered MI cases (51). All other diagnoses were validated 
by examining a complete list of relevant diagnoses and procedure codes recorded in the 
DNPR for each individual participant. The cohort was followed from baseline until the 
first registration of MI, death, emigration or end of follow-up in July 2013.  
 
Ischemic stroke 
Participants registered with a primary or secondary discharge diagnosis of stroke 
(ICD-8: 430, 431, 433, 434, 436.01, or 436.90, or ICD-10: DI60, DI61, DI63, or 
DI64) in the DNPR until November 2009 were identified (52). All potential stroke 
cases were validated by review of medical records and subsequently subtyped into 
ischemic stroke subtypes according to the TOAST classification (23) based on 
clinical findings, brain imaging, imaging of extracranial arteries, laboratory tests, 
electrocardiograms, and echocardiography (52). The cohort was followed from 
baseline until first registration of stroke, death, emigration or end of follow-up in 
November 2009. 
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PAD 
Participants registered with a primary or secondary discharge diagnosis of PAD (ICD-
8: 44390, 44500, 44509, 44590, 44599, 44020 or 44030, or ICD-10: DI702, DI702A 
and DI739A-C) until December 2009 were identified. Subsequently, all potential 
cases of PAD were validated by review of medical records (53). The cohort was 
followed from baseline until first registration of PAD, death, emigration or end of follow-
up in December 2009. 
 
4.6 METHODOLOGICAL CONSIDERATIONS 
Study designs 
We used a traditional follow-up strategy to investigate the associations between ALA 
intake and the rate of MI, ischemic stroke and PAD, while a case-cohort design was 
used to investigate associations between adipose tissue content of ALA and the rate 
of MI, ischemic stroke and PAD (Figure 2). In a case-cohort design, the study is nested 
within a cohort followed over time, but the exposure information is only required from 
cases and from a randomly drawn sample of the cohort. During statistical analysis, the 
random sample representing the exposure and covariates distribution in the total 
cohort can be weighted to adjust for the overrepresentation of cases in the case-cohort 
dataset. In the DCH cohort a randomly drawn sub-cohort of 3,500 participants was 
used to represent the adipose tissue content of ALA and covariate distribution within 
the whole cohort. The major advantage of the case-cohort design is that the sub-cohort 
can be used as a comparison group for studying different diseases without identifying 
a new set of controls for each disease as required in a nested case-control study. The 
use of a case-cohort design in our studies limited the costs for the number of expensive 
fatty acid analyses of adipose tissue samples significantly. 
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Figure 2. Illustration of the principle of a traditional follow-up design and a case-
cohort design.  
 
 
Exposures of interest  
In analyses of dietary intakes of ALA, we decided to energy-adjust intake of ALA 
using the residual method (54). Total energy intake is largely determined by body 
size, physical activity, and metabolic efficiency and is typically relative constant 
unless changes in weight or physical activity occur (55). Thus, intake of ALA in 
individuals is likely to be altered mainly by changing the composition of the diet rather 
than the amount of food. In addition, studies have shown that total energy intake may 
be inversely associated with the risk of CHD possibly mediated by health benefits of 
physical activity and adjustment for total energy intake may be important for reducing 
confounding (55).  
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Adipose tissue content of ALA was expressed as area percentage of the total of fatty 
acids in adipose tissue (relative fatty acid concentrations are often used in biomarker 
studies of fatty acids).  
 
Risk factors  
A large number of risk factors have been documented or proposed for MI and ischemic 
stroke, while risk factors for PAD have been less studied. Identification of risk factors 
in the papers included in this thesis was based on review of the literature and potential 
risk factors were pre-specified prior to data analysis. An overview of the covariate 
adjustments used is presented in Table 1. Shared and established risk factors for MI, 
ischemic stroke and PAD include age, educational level, physical activity, alcohol 
consumption, hypercholesterolemia, hypertension and diabetes mellitus. Although, 
MI, ischemic stroke and PAD may share pathophysiological similarities, differences 
in associated risk factors and their importance for disease risk may differ among these 
outcomes. Studies have suggested that the risk of MI may differ by sex (56,57), while 
the association between sexes and ischemic stroke and PAD is less clear. Therefore, 
we decided to conduct analyses of MI separately among men and women (sex-
specific), whereas sex-stratified analyses were conducted for analyses of ischemic 
stroke and PAD by allowing for different baseline hazards among men and women. 
In addition, sex-specific analyses would not have allowed for investigation of 
associations with ischemic stroke subtypes and a detailed control for confounding in 
analyses of ischemic stroke subtypes and PAD due to a relatively low number of 
female cases. Menopausal status and use of hormone replacement therapy have been 
suggested as risk factors for MI (58,59), whereas their role in ischemic stroke and 
PAD is less clear. With respect to atrial fibrillation/flutter this is an important risk 
factor for ischemic stroke, but not for MI and PAD. Age is probably the most 
important risk factor for MI, ischemic stroke and PAD and was therefore taken into 
account in all analyses. In addition, we decided to include baseline age as a covariate 
in analyses on ischemic stroke and PAD to ensure comparison of participants for 
whom exposure information was of comparable age.  
During review of the literature, we identified several potential dietary risk factors that 
might influence CHD risk including total energy intake, glycemic load and dietary 
intakes of fibre, monounsaturated fatty acids, saturated fatty acids, LA and LC n-3 
PUFAs.  
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Statistical models 
We defined four different models as presented in Table 1. Model 1A was controlled 
for age and sex, while model 1B included additional adjustment for established risk 
factors. The minimally adjusted model 1A was presented in order to evaluate the 
importance of potential confounding by comparing with the point estimates of model 
1B as large differences might indicate confounding. However, no conclusions should 
be drawn from the minimally adjusted model 1A due to the risk of confounding. 
In model 2, we included the covariates in model 1B and co-morbidities, which are 
considered important risk factors for the outcomes of interest. However, the rather 
broad range of proposed mechanisms for the effects of ALA imply that these co-
morbidities may be considered potential intermediate steps in the causal pathway 
between ALA and the risk of the outcomes of interest.  
The interpretation of model 2 is complicated because adjustment for these co-
morbidities in part might eliminate the pathway through these mediators resulting in 
attenuation of observed associations and/or introduce collider stratification bias. 
However, these potential mediators are presumably only affected by ALA to a limited 
extent and not taking the presented comorbidities into account might result in residual 
confounding.  
In supplemental analyses of dietary intake of ALA, we adjusted for established risk 
factors and potential dietary risk factors including total energy intake, glycemic load 
and dietary intake of fibre, monounsaturated fatty acids, saturated fatty acids, LA and 
LC n-3 PUFAs (model 3) in order to address potential confounding from the diet. 
However, measures of association obtained from analyses including adjustment for 
diet are difficult to interpret because restrictions into the underlying dietary pattern 
are introduced and these differences may not be reasonable within ordinary dietary 
patterns limiting the public health relevance. Therefore, given the interpretational 
complexities of model 2 and 3, we consider model 1B the most appropriate for 
interpretation.  
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Table 1. Overview of the covariate adjustments according to outcomes of interest.  
  
MI 
 Ischemic 
stroke 
  
 PAD 
 sex-
specific 
 sex-
stratified 
 sex-
stratified 
Model 1A         
Baseline age (years, spline)     3kn   5kn 
Model 1B         
Smoking (never; former; current (1-4, 15-24, >24 g/d))         
Physical activity (inactive, moderately inactive, 
moderately active, active) 
        
Length of schooling (£7yrs; 8-10 years; >10yrs)         
Waist circumference (cm, spline)  5kn      5kn 
Body mass index (kg/m2, spline)  5kn      5kn 
Waist circumference adjusted for BMI (cm, spline)     3kn    
Menopausal status (pre; post; unknown)1         
Hormone replacement therapy (yes; no; unknown)1         
Alcohol intake (g/d, spline)  5kn   3kn   5kn 
Model 2         
History of hypercholesterolemia (yes; no; unknown)         
History of hypertension (yes; no; unknown)         
History of diabetes mellitus (yes; no; unknown)         
History of atrial fibrillation (yes; no; unknown)         
Model 3 (Supplemental analyses)2         
Total energy intake (kJ/day)  5kn   3kn   5kn 
Glycemic load  5kn   3kn   5kn 
Fibre (g/day)  5kn   3kn   5kn 
Monounsaturated fatty acids (g/day)  5kn   3kn   5kn 
Saturated fatty acids (g/day)  5kn   3kn   5kn 
Linoleic acid (g/day)  5kn   3kn   5kn 
LC n-3 PUFAs (g/day)  5kn   3kn   5kn 
Abbreviations: Kn, knots (3 or 5) in a restricted cubic spline; BMI, Body mass index 
1 Women only 
2 Dietary analyses of ALA only 
 
 
4.7 STATISTICAL ANALYSES 
We used time-to-event analysis to investigate associations between dietary intake and 
adipose tissue content of ALA and the risk of MI, ischemic stroke or PAD. Hazard 
rate ratios (HRs) with 95% CIs, calculated using Cox proportional hazard regression, 
were used as measures of association. We used age as underlying time scale in all 
analyses.  
We decided to assess the shape of the associations by analysing estimates of ALA 
exposure as a continuous variable by the use of restricted cubic splines. Categorical 
analyses using ALA divided into quintiles of exposure using the lowest quintile as 
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reference were also undertaken, but the continuous analyses were considered the 
primary analyses. We decided to express ALA exposure using restricted cubic splines 
with 3 knots placed at the 10th, 50th and 90th percentile as described by Harrell (60). 
The median ALA exposure was used as reference, and the spline functions were 
formally tested against a horizontal line using Wald’s test. In sensitivity analyses, we 
investigated the robustness of the models by modifying the location of the knots and 
by increasing the number of knots.  
The associations between adipose tissue content of ALA and the outcomes of interest 
were investigated using weighted Cox proportional hazard regression. Several 
different weighting schemes has been suggested, and we used the weighting scheme 
described by Kalbfleisch and Lawless (61) because this approach has previously been 
reported to perform well in a study that compared the most commonly used case-
cohort estimators (62). Thus, all cases were assigned a weight equal to one, whereas 
all non-cases in the sub-cohort were assigned a weight calculated as the ratio between 
the number of non-cases in the cohort divided by the number of non-cases in the sub-
cohort. Individual weights were calculated for each outcome of interest.  
We entered the covariates into four different models as shown in Table 1. In analyses 
of MI and PAD, we included all continuous risk factors as restricted cubic splines 
using 5 knots to ensure the best possible adjustment for these covariates. However, in 
analyses of ischemic strokes we limited the complexity of the statistical models due 
to the relatively low number of cases of the most uncommon ischemic stroke subtypes 
by reducing the number of knots for continuous covariates to three and by including 
waist circumference adjusted for BMI instead of including waist circumference and 
BMI separately into the models.  
The proportional hazard assumption was evaluated by plotting the scaled Schoenfeld 
residuals against age at event assessing potential violations visually using fractional 
polynomial regression for each covariate. An approximate horizontal line indicated 
constant hazard ratios over time and fulfilment of the proportional hazard assumption.  
All statistical analyses were conducted using Stata statistical software and a p-value 
below 0.05 was considered statistically significant. Measures of association that did 
not reach conventional statistically significance was described as indications of 
associations when considered appropriate bearing in mind that statistically non-
significant associations should not be interpreted as absence of associations (63).  
The background dietary pattern was described using radar plots for a selected number 
of foods and beverages . Intake of foods was energy-adjusted using the residual 
method (54).   
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CHAPTER 5. STUDIES 
5.1 OVERVIEW 
We aimed to investigate the associations between the energy-adjusted dietary intake 
and adipose tissue content of ALA and the rate of incident ASCVD. We hypothesized 
that dietary intake and adipose tissue content of ALA were inversely associated with 
the rate of incident MI, ischemic stroke and PAD. These results of our studies have 
been reported in five papers: 
Paper I: Dietary intake and adipose tissue content of alpha-linolenic acid and risk of 
myocardial infarction: a Danish cohort study. 
 
Paper II: Dietary intake of alpha-linolenic acid is not appreciably associated with 
the risk of ischemic stroke among middle-aged Danish men and women. 
 
Paper III: Adipose tissue content of alpha-linolenic acid and the risk of ischemic 
stroke and ischemic stroke subtypes: a Danish case-cohort study. 
 
Paper IV: Intake of alpha-linolenic acid is not consistently associated with a lower 
risk of peripheral artery disease: results from a Danish cohort study. 
 
Paper V: Adipose tissue content of alpha-linolenic acid and development of 
peripheral artery disease: a Danish case-cohort study.  
 
In the following, the papers outlined above will be summarised according to the 
outcomes of interest including MI (paper 1), ischemic stroke (papers 2 and 3) and 
PAD (papers 4 and 5).  
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5.2 ALA AND MI 
Aim 
To investigate the associations between dietary intake and adipose tissue content of 
ALA and the rate of MI.  
Key methods 
Incident cases of MI were identified through the DNPR and the Danish Causes of 
Death Registry. The association between ALA intake expressed as energy-adjusted 
intake in g/d and MI was investigated using a follow-up design. The association 
between adipose tissue content of ALA and MI was investigated using a case-cohort 
design in which the adipose tissue content of ALA expressed as a percentage of total 
fatty acids in all cases and in a randomly drawn sample from the cohort (sub-cohort). 
Analyses were conducted separately among men and women and HRs obtained from 
Cox proportional hazard regression analyses were used as measures of association.  
Main results 
During 17 years of follow-up, 2,124 men and 854 women developed MI for whom 
adipose tissue biopsies were available in 1,994 men and 770 women (Figure 3 and 
Table 2).  
In multivariable analyses with ALA intake modelled as a spline adjusted for 
traditional risk factors for MI (model 1B), an indication of a weak and statistically 
non-significant positive association was observed between ALA intake and the rate 
of MI in men, whereas an indication of a weak statistically non-significant U-shaped 
association was found in women. Analyses of the associations between quintiles of 
ALA intake and the rate of MI are summarized in Figure 4. Supplemental analyses 
including additional adjustment for dietary factors are presented in Appendix Figure 
1. 
Multivariable analyses with ALA content in adipose tissue modelled as a spline 
adjusted for established risk factors for MI (model 1B) indicated a statistically non-
significant positive association between the content of ALA in adipose tissue and the 
rate of MI in men, whereas an indication of a weak statistically non-significant U-
shaped association was observed in women. Analyses of the associations between 
adipose tissue content of ALA in quintiles and the rate of MI in men and women are 
given in Figure 4.  
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Figure 3. Flowchart for the DCH cohort and incident MI cases identified among men 
and women with complete information on exposures and other covariates of interest.  
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Figure 4. Forest plot of the associations between quintiles of energy-adjusted ALA 
intake and the rate of MI in analyses including adjustment for established risk factors 
(model 1B).  
 
Conclusion 
ALA intake was not appreciably associated with the rate of MI. An indication of a 
weak positive association between adipose tissue content of ALA was observed in 
men and a weak U-shaped association in women was observed, but these associations 
were not statistically significant.  
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5.3 ALA AND ISCHEMIC STROKE 
Aim 
To investigate the association between dietary intake and adipose tissue content of 
ALA and the rate of ischemic stroke and ischemic stroke subtypes.  
Key methods 
Incident cases of ischemic stroke were identified through the DNPR, validated and 
classified into subtypes according to the TOAST criteria. ALA intake was expressed 
as energy-adjusted intake in g/d and analysed using a follow-up design, whereas 
adipose tissue content of ALA was analysed using a case-cohort design. HRs obtained 
from Cox proportional hazard regression analysis were used to describe the 
associations between intake and adipose tissue content of ALA and the rate of 
ischemic stroke and its subtypes allowing for different baseline hazards among sexes. 
Main results 
During a median of 13.5 years of follow-up, 1,859 ischemic strokes occurred with 
content of ALA in adipose tissue  available in 1,735 cases (Figure 5 and Table 3).  
Multivariable analyses with ALA modelled as a spline adjusted for traditional risk 
factors for ischemic stroke (model 1B) indicated a weak statistically non-significant 
positive association between ALA intake and the rate of total ischemic stroke. In 
analyses of ischemic stroke subtypes, indications of a weak statistically non-
significant inverse associations were observed between ALA intake and ischemic 
stroke due to large artery atherosclerosis (316 cases), whereas an indication of a weak 
statistically non-significant positive association was seen between ALA intake and 
ischemic stroke due to small-vessel occlusions (835 cases). Analyses of the 
associations with ALA intake in quintiles are presented in Figure 6. Analyses 
including additional adjustment for dietary factors are presented in Appendix Figure 
1. 
Multivariable analyses with ALA modelled as a spline adjusted for ischemic stroke 
risk factors (model 1B) indicated a statistically non-significant U-shaped association 
between ALA content in adipose tissue and the rate of total ischemic stroke. In 
analyses of ischemic stroke subtypes, a statistically significant U-shaped association 
was observed between adipose tissue content of ALA and the rate of ischemic stroke 
due to large artery atherosclerosis (297 cases), whereas no appreciable association was 
found between ALA content in adipose tissue and the rate of ischemic stroke due to 
small-vessel occlusions (772 cases). Analyses of the associations with ALA content 
in adipose tissue in quintiles are presented in Figure 6. 
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Figure 5. Flowchart for the DCH cohort and incident total ischemic stroke cases 
identified participants with complete information on exposures and other covariates 
of interest. 
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Table 3. Baseline characteristics of the cohort, sub-cohort and participants that 
developed ischemic stroke during follow-up. 
 ALA intake and 
 ischemic stroke 
ALA in adipose tissue and 
ischemic stroke 
Cohort 
(n = 55,018) 
Cases 
(n = 1,859) 
Sub-cohort 
(n = 3,185) 
Cases 
(n = 1,735) 
Sex (%)      
 Men 47.6 61.7 54.1 61.8 
 Women 52.4 38.4 45.9 38.2 
Age at enrolment (years)1 56.1 58.8 56.3 58.8 
Length of schooling (%)     
 ≤7 years 32.7 40.4 32.7 40.7 
 8-10 years 46.1 42.7 45.0 42.7 
 >10 years 21.1 16.9 22.3 16.6 
Smoking (%)     
 Never 35.4 24.2 34.8 24.6 
 Former 28.8 25.4 29.3 25.8 
 Current <15 g/d 13.0 15.5 13.5 15.5 
 Current 15-25 g/d 16.1 24.2 15.7 23.8 
 Current >25 g/d 6.8 10.8 6.8 10.3 
Physical activity (%)     
 Inactive 10.7 14.9 11.0 14.7 
 Moderately inactive 30.3 30.3 30.4 30.2 
 Moderately active 24.2 21.8 23.7 21.4 
 Active 34.8 33.0 35.0 33.7 
Waist circumference (cm)1 88.9 93.0 91.1 93.6 
Alcohol intake (g/d)1 13.0 14.6 13.9 14.5 
Co-morbidities (%)     
 Hypercholesterolemia 7.3 10.4 7.8 10.7  
Hypertension 16.0 28.0 15.6 28.4  
Diabetes mellitus 2.0 4.5 2.0 4.2 
Atrial fibrillation 0.7 1.5 0.9 1.4 
1 Median 
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Figure 6. Forest plot of the associations between quintiles of ALA and the rate of 
ischemic stroke in analyses including adjustment for established risk factors (model 
1B).  
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Conclusion 
ALA intake was not consistently nor appreciably associated with the rate of total 
ischemic stroke or ischemic stroke subtypes of atherosclerotic origin. Adipose tissue 
content of ALA may be U-shapedly associated with the rate of total ischemic stroke 
and ischemic stroke due to large artery atherosclerosis, while no appreciable 
association was observed for ischemic strokes due to small-vessel occlusions.  
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5.4 ALA AND PAD 
Aim 
To investigate the associations between dietary intake and adipose tissue content of 
ALA and the rate of PAD.  
Key methods 
Incident cases of PAD were identified by linkage with the DNPR. Subsequently, all 
cases were validated. The energy-adjusted intake of ALA in g/d was calculated for 
each participant and an association with PAD was investigated using a follow-up 
design, while the association between adipose tissue content of ALA was determined 
in all cases and in the sub-cohort and analysed by a case-cohort design. We used HRs 
obtained from Cox proportional hazard regression to investigate the associations 
between intake and adipose tissue content of ALA and the rate of PAD allowing for 
different baseline hazards among sexes. 
Main results 
During a median of 13.5 years of follow-up, 950 cohort participants developed PAD 
with adipose tissue content of ALA being available in 863 cases (Figure 7 and  
Table 4).  
In multivariable analyses with ALA modelled as a spline adjusted for traditional PAD 
risk factors (model 1B), an indication of a weak statistically non-significant inverse 
U-shaped association was observed between ALA intake and the rate of PAD. 
Analyses of the associations between ALA intake in quintiles and the rate of PAD are 
shown in Figure 8. Analyses including additional adjustments for dietary factors are 
presented in Appendix Figure 1.  
Multivariable analyses with ALA modelled as a spline adjusted for traditional PAD 
risk factors (model 1B) indicated a statistically non-significant U-shaped association 
between ALA content in adipose tissue and the rate of PAD. Categorical analyses of 
associations between ALA intake in quintiles and the rate of PAD are shown in Figure 
8.  
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Figure 7. Flowchart for the DCH cohort and incident PAD cases identified among 
participants with complete information on exposures and other covariates of interest. 
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Table 4. Baseline characteristics of the cohort, sub-cohort and participants that 
developed PAD during follow-up. 
 ALA intake and 
 ischemic stroke 
ALA in adipose tissue and 
ischemic stroke 
Cohort 
 (n =55,248) 
Cases 
(n = 950) 
Sub-cohort 
 (n = 3,197) 
Cases 
(n = 863) 
Sex (%)      
 Men 47.7 62.1 54.1 61.7 
 Women 52.3 37.9 46.0 38.4 
Age at enrolment (years)1 56.1 58.6 56.3 58.5 
Length of schooling (%)     
 ≤7 years 32.7 48.0 32.7 47.1 
 8-10 years 46.2 40.2 45.1 40.9 
 >10 years 21.1 11.8 22.3 12.1 
Smoking (%)     
 Never 35.4 4.8 34.9 5.1 
 Former 28.9 18.0 29.3 18.1 
 Current <15 g/d 13.0 19.0 13.5 19.5 
 Current 15-25 g/d 16.0 40.4 15.6 39.9 
 Current >25 g/d 6.8 17.7 6.7 17.5 
Physical activity (%)     
 Inactive 10.8 16.3 11.0 16.8 
 Moderately inactive 30.4 32.0 30.3 32.4 
 Moderately active 24.2 21.2 23.7 20.5 
 Active 34.7 30.5 35.0 30.2 
Waist circumference (cm)1 89.0 91.3 90.0 92.0 
Body mass index (kg/m2)1 25.5 25.5 25.8 25.6 
Alcohol intake (g/d)1 12.9  16.5 13.8 17.0 
Co-morbidities (%)     
 Hypercholesterolemia 7.4 13.8 8.0 13.8  
Hypertension 16.1 27.8 15.9 27.9  
Diabetes mellitus 2.0 10.7 2.0 9.9 
1 Median 
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Figure 8. Forest plot of the associations between quintiles of ALA and the rate of 
PAD in analyses including adjustment for established risk factors (model 1B).  
 
Conclusions 
ALA intake was not appreciably associated with the rate of PAD.  Indications of a U-
shaped association between adipose tissue content of ALA was observed, but the 
association were not statistically significant.  
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5.5 ALA AND THE UNDERLYING DIETARY PATTERN 
We used radar plots to graphically describe our exposures of interest as indicators of 
an underlying dietary pattern.  
Participants in the highest quintile of energy-adjusted ALA intake had higher intakes 
of vegetable oils and mayonnaises, margarines, butter and other animal fat, eggs, 
processed and red meat, fish, poultry, snacks and fatty potatoes, soft drinks and juices, 
alcohol, refined cereals and potatoes, and lower intakes of fruits, vegetables and dairy 
products (Figure 9A).  
Participants in the highest quintile of adipose tissue content of ALA within the sub-
cohort had higher intakes of vegetable oils and mayonnaises, margarines, butter and 
other animal fat, processed meat, fish and refined cereals, and lower intakes of fruits, 
vegetables, dairy products, peanuts, snacks and fatty potatoes, soft drinks and juices 
and alcohol (Figure 9B).  
 
 
A 
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Figure 9. Radar plot of the median intake of selected foods in the highest ( ) and 
lowest ( ) quintile of ALA intake in the cohort (A) or quintile of adipose tissue 
content of ALA in the sub-cohort (B) indexed according to the median in the study 
populations described in paper IV and paper V, respectively. 
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CHAPTER 6. DISCUSSION 
We found that dietary intake of ALA was not consistently nor appreciably associated 
with the rate of incident MI, total ischemic stroke or ischemic strokes of presumed 
atherosclerotic origin or with PAD. However, we did observe a U-shaped pattern of 
associations between ALA content in adipose tissue and the rate MI in women and 
between ALA content in adipose tissue and the rate of total ischemic stroke, ischemic 
stroke due to large artery atherosclerosis and PAD although only statistically 
significant in analyses of ischemic stroke due to large artery atherosclerosis. Overall 
our studies therefore did not lend support to our hypothesis that our estimates of ALA 
exposure were inversely associated with incident MI, ischemic stroke or PAD.  
 
6.1 STRENGTHS AND LIMITATIONS 
The strength and limitations of the studies included in this thesis have been described 
in detail in the individual papers, but some issues will be discussed below.  
Selection problems 
Selection bias may arise from procedures used to select participants and from factors 
that may influence study participation when related to both exposure and outcome of 
interest. Selection bias is, however, not likely to be a major concern in our studies 
because information on exposures was collected independently of the outcomes of 
interest and all cases were ascertained using nationwide registers with very limited 
loss to follow-up.  
Information problems 
Information problems may arise from inaccurate assessment of the exposures and/or 
misclassification of the outcomes of interest.  
Information on dietary intake of ALA is likely to have been subject to measurement 
error as we relied on information on diet obtained through a single FFQ designed to 
assess the average intake of selected foods and beverages during the previous year. 
Further, calculation of estimated ALA intake based on specified portion sizes and the 
use of food composition tables may have contributed with error. Measurement error 
of dietary exposures is inevitable although it may be reduced using analytical 
approaches such as energy-adjustment (54). The FFQ used in the DCH cohort has 
been validated against two times 7-days weighted diet records and found suitable to 
categorise subjects according to their intake of energy and PUFAs, but intake of ALA 
was not specifically validated (45). However, measurement error in the assessment of 
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ALA intake probable occurred at random as information on diet was collected 
independently of the outcomes of interest. Random measurement error generally leads 
to attenuation of observed associations and loss of statistical power. Indeed, repeated 
dietary measurements would have been preferable in order to reduce random 
measurement errors and to capture potential changes in dietary habits during follow-
up. However, the content of ALA in human tissue may represent an objective marker 
of intake that may be less prone to measurement error. The use of biomarkers as 
measures of exposure may be of particular importance to reflect ALA exposure, 
because sources rich in ALA such as some plant oils and margarines are used in food 
preparation and therefore may be difficult to report (11). Adipose tissue content of 
ALA is considered the gold standard to reflect the long-term exposure of ALA 
(64,65), but the content of ALA in adipose tissue may be influenced by metabolism 
and intake of other fatty acids. However, the content of ALA in adipose tissue may 
provide an estimate of the endogenous exposure, which may be more important from 
a biological point of view.  
Confounding 
We included detailed adjustment for potential risk factors defined prior to data 
analysis, but residual confounding arising from inaccurate self-reported information 
on covariates, insufficient adjustment and risk factors not taken into account cannot 
be ruled out in our analyses.   
We applied adjustment for risk factors in different models. In general, the observed 
associations for each outcome in the minimally adjusted models taking into account 
age and sex (1A) were weakened after additional adjustment for established risk 
factors (model 1B), which might indicate confounding from these factors. Additional 
adjustment for comorbidities (model 2) showed overall similar pattern of associations 
compared with results obtained from analyses including adjustment for established 
risk factors (model 1B). This might suggest that residual confounding from the 
included comorbidities (model 2) might not be of major importance although findings 
from these models should be interpreted with caution as the included comorbidities 
might be intermediates.  
In supplemental analyses, we added potential dietary risk factors to model 1B in 
analyses of ALA intake (model 3). Overall similar pattern of associated compared to 
model 1B were observed. We did not have information on intake of trans fatty acids, 
which would have been preferable as some early studies investigating ALA intake in 
relation to risk of CHD reported positive correlations between intake of ALA and 
trans fatty acid intake (33,66). However, the content of trans fatty acids in margarines, 
an important source of ALA, was reduced by more than 50% in the early 1990s in 
Denmark, and in the late 1990s trans fatty acids were practically absent in Danish 
margarines (67). Nevertheless, interpretation measures of associations obtained from 
analyses including adjustment for dietary factors should be interpreted with great 
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caution because fatty acids may share food sources and adjustment for dietary factors 
may introduce restrictions in the underlying dietary pattern that are not comparable 
with the underlying dietary pattern explored in model 1B.  
We used radar plots to describe dietary intake and adipose tissue content of ALA as 
indicators of an underlying dietary pattern and to evaluate potential confounding from 
the underlying dietary pattern. These radar plots indicated that the energy-adjusted 
intake of ALA, but also adipose tissue content of ALA, were indicators of complex 
underlying dietary patterns. However, the radar plots did not indicate that a high intake 
or adipose tissue content of ALA reflected overall healthy dietary patterns.  
Generalizability 
The generalizability of the findings in this thesis may be limited according to the 
eligibility criteria for being invited to participate in the DCH cohort study and the 
exclusion criteria applied to the study populations under study. Thus, our findings 
may not be generalized to individuals who have not survived until the age of 50 years 
without a previous diagnosis of cancer and the outcome of interest in each study. Also, 
the participants enrolled into the DCH cohort was recruited from selected areas in 
Denmark and included almost exclusively Causations. In addition, only 35% of those 
invited to participate in the DCH cohort agreed to participate and those enrolled had 
a higher socioeconomic position compared with invited non-participants (43).  
 
6.2 ALA AND SUGGESTED MECHANISMS OF ACTION 
We studied the incorporation and metabolism of ALA and LA cultured in EA.hy926 
endothelial cells and the production of inflammatory mediators when exposed to 
ALA, LA or different concentrations of ALA and LA followed by stimulation with 
tumour necrosis factor alpha (68). In these in vitro experiments, we found that ALA 
was incorporated into endothelial cells and that cells incubated with ALA had a higher 
absolute content of eicosatetraenoic acid, EPA and DPA, but not DHA, compared to 
endothelial cells cultured in culture medium (68). Further, the medium of endothelial 
cells incubated with ALA had a lower concentration of vascular endothelial growth 
factor, regulated on activation normal T cell expressed and secreted, intercellular 
adhesion molecule-1, monocyte chemoattractant protein-1 and interleukin-6, but not 
interleukin-8, when comparing with endothelial cells cultured in culture medium (68). 
These findings suggest that ALA can be further elongated in EA.hy926 endothelial 
cells and that incubation with ALA may lower various aspects of inflammation in 
these cells.  
In humans, ALA intake has also been ascribed anti-inflammatory properties although 
results have not been consistent (11,12). Several cross-sectional studies have reported 
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inverse associations between ALA intake or content of ALA in blood components and 
plasma levels of C-reactive protein (69–73), IL-6 (69) and its soluble recepter (74), 
IL-1ra (73), soluble vascular cell adhesion molecule-1 (75) and E-selection (69,75). 
Also, intervention studies have suggested that supplementation with ALA or foods 
rich in ALA may lower aspects of inflammation (76–81).   
Several studies investigating increased ALA consumption on blood lipid 
concentrations have suggested that ALA may have a LDL-cholesterol lowering effect, 
but studies have shown inconsistent findings and effects on triglycerides and other 
lipoproteins are less clear (12). Also, studies investigating increased ALA 
consumption on blood pressure have shown conflicting results, but few studies have 
reported modest inverse associations between ALA exposure and blood pressure (12). 
Also, ALA has been hypothesized to lower platelet aggregation (11,82). Furthermore, 
few follow-up studies have reported inverse associations between ALA intake and 
circulating levels of ALA and the risk of incident type 2 diabetes mellitus (83–85). 
Thus, several potential health benefits of ALA exposure have been suggested that 
might contribute to reduced atherosclerosis. Interestingly, studies have supported that 
ALA intake or content in serum and erythrocytes may be inversely associated with 
carotid intima media thickness and plaque burden in the carotid and femoral arteries 
(86–88).  
 
6.3 OBSERVATIONAL STUDIES OF AN ASSOCIATION BETWEEN 
ALA AND ASCVD 
Several follow-up studies have investigated the association between dietary intake of 
ALA and CHD (10) (Figure 10). A possible association with ischemic stroke has been 
less studied (89) and no reported follow-up study has investigated associations 
between ALA intake and the rate of ischemic stroke subtypes or PAD. Also, no 
reported follow-up studies have reported on an association between adipose tissue 
content of ALA and the risk of MI, ischemic stroke or PAD. 
 
ALA and CHD 
Early findings reported by Ascherio et al. (90) based on data from the US Health 
Professionals Follow-up study suggested indications of a lower rate of incident CHD 
(non-fatal MI and fatal CHD) when comparing the highest quintile of ALA intake 
with the lowest, but no consistent pattern of association was observed across quintiles. 
A statistically significant inverse association was observed when ALA was expressed 
as a percentage of total energy intake in continuous linear analyses including 
adjustment for traditional risk factors and potential dietary risk factors (90). An 
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updated report from the same population by Mozaffarian et al. (91) after 14 years of 
follow-up found a lower rate of CHD with higher ALA intake in subjects with a low 
intake of EPA+DHA (<100 mg/day), while no association was observed among 
subjects with a higher intake of EPA+DHA (³100 mg/day). The median intake of 
EPA+DHA intake within the DCH cohort was, however, markedly higher than in the 
Health Professionals Follow-up study and stratified analyses with a sufficient 
statistical power at such low levels was not possible.  
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Figure 10A+B. Follow-up studies investigating ALA intake and incident CHD. 
Presented point estimates were selected from models that included adjustment for risk 
factors without including dietary risk factors whenever possible. 
1 ALA intake as a percentage of total energy intake; 2 ALA intake as a percentage of 
total fatty acids 
 
Several other studies have not confirmed inverse association between ALA intake and 
the rate of CHD (33,66,92–98). Also, a pooled analysis by Vedtofte et al. (99) 
including data from eight American and European cohorts did not find ALA intake 
associated with the rate of total CHD after adjustment for traditional risk factors. 
However, in analyses including adjustment for traditional risk factors and dietary risk 
factors indications of lower rates of total CHD and fatal CHD in men were observed, 
whereas no appreciable association was observed amongst women (99).  
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Some studies have reported inverse or indications of inverse associations between 
ALA intake and fatal CHD (33,98–101), but the results have not been consistent 
(33,66,92,93,96,98–101). In supplemental analyses, we observed an inverse U-shaped 
association between ALA intake and fatal MI and a J-shaped association between 
adipose tissue content of ALA and fatal MI among men, but these associations were 
not statistically significant. Interestingly, a study by Albert et al. (93) observed lower 
rates of sudden cardiac death with higher ALA intake and suggested that ALA may 
influence cardiovascular risk predominantly through effects on fatal arrhythmias as 
no associations was observed between intake of ALA and non-fatal MI or other fatal 
CHD events.  
Limited knowledge is available on the association between adipose tissue content of 
ALA and CHD, but a case-control study from Costa Rica by Campos et al. (102) 
reported a statistically significant inverse association between adipose tissue content 
of ALA and the odds of non-fatal MI. However, findings from other case-control 
studies investigating adipose tissue content and the odds of MI have not been 
consistent (103–105) (Figure 11).  
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Figure 11. Case-control studies investigating adipose tissue content of ALA and MI. 
Presented point estimates were selected from models that included adjustment for risk 
factors without including dietary risk factors whenever possible. All studies expressed 
adipose tissue content as a percentage of total fatty acids.  
 
A pooled analysis by Gobbo et al. (106) did not find biomarkers of ALA including 
the content of ALA in plasma, phospholipids, cholesterol esters and adipose tissue 
associated with total CHD (6,960 cases), but reported a modest inverse association 
between biomarkers of ALA and fatal CHD (2,640 cases). However, a Swedish 
follow-up study found no association between adipose tissue content of ALA and the 
rate of cardiovascular death (107).  
In summary, follow-up studies investigating the association between ALA intake and 
incident CHD have shown conflicting results, but most studies have not supported an 
inverse association. However, ALA intake may be associated with a lower risk of 
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CHD in subjects with a low intake of LC n-3 PUFAs although this hypothesis warrants 
further investigation. Studies investigating biomarkers of ALA exposure have also 
shown conflicting results.  
 
ALA and ischemic stroke 
Few studies have investigated an association between ALA intake and the rate of total 
ischemic stroke (94,96,98,108) (Figure 12). Interestingly, a study by Goede et al. (94) 
observed lower rates of total ischemic stroke across quintiles of ALA and a study by 
Fretts et al. (96) found an indication of lower rates of total ischemic stroke when 
comparing the highest quintile of ALA intake with the lowest although no consistent 
pattern of association was observed across quintiles. In contrast, two other follow-up 
studies supported our findings of no association between ALA intake and the rate of 
total ischemic stroke (98,108). Also, most nested case-control studies investigating 
ALA content in blood components do not support that ALA exposure is consistently 
nor appreciably associated with the risk of total ischemic stroke (96,109–113). 
Previous follow-up studies have not investigated intake or adipose tissue content of 
ALA in relation to ischemic stroke subtypes. However, a nested case-control study by 
Iso et al. (109) reported lower odds of lacunar infarctions and large artery occlusive 
infarctions with higher ALA content in serum, but these associations were not 
statistically significant and detailed adjustment for risk factors were not undertaken.  
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Figure 12. Follow-up studies investigating ALA intake and total ischemic stroke. 
Presented point estimates were selected from models that included adjustment for risk 
factors without including dietary risk factors whenever possible. 
1 ALA intake as a percentage of total fatty acids; 2 ALA intake as a percentage of total 
energy intake 
 
 
ALA and PAD 
To our knowledge, no previous follow-up studies have investigated the association 
between dietary intake or adipose tissue content of ALA and the rate of PAD. 
However, a cross-sectional study reported lower odds of lower limb disease with ALA 
content in erythrocytes (114), but detailed adjustment for risk factors were not 
performed.  
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6.4 CLINICAL SUPPLEMENTATION TRIALS WITH ALA 
Few clinical trials have investigated the effect of ALA supplementation of or foods 
rich in ALA on vascular outcomes. 
 
In a Norwegian trial (115), 13,406 men aged 50 to 59 years were randomised to 
receive either 10 mL of refined linseed oil (rich in ALA) or sunflower oil (rich in LA) 
both supplemented with vitamin E (116). The subjects were followed for one year and 
no difference in the number of incident MIs, fatal CHD or deaths were observed 
between the two groups (115). However, this study was initiated in 1965 and was 
hampered by few cases and a poor compliance to the supplement regimens.  
In the randomized single-blinded Lyon Diet Heart Study (14), 605 patients aged less 
than 70 years of age with a prior MI were randomly assigned to either a 
Mediterranean-type diet supplemented with an ALA-rich margarine based on canola 
oil (providing 1.5 g/d of ALA) or a prudent Western diet (controls) (14,117). Patients 
assigned to the active group also received dietary counselling including advice to use 
canola oil and olive oil for salads and food preparation, to eat more bread, root 
vegetables, green vegetables, fish and fruits, and to lower their intake of red meat by 
replacing it with poultry and lower their intake of butter and cream by use of the ALA-
rich trial provided margarine (14). After 27 months of follow-up, an intermediate 
analysis showed a substantially lower rate (HR: 0.27, 95% CI: 0.12-0.59) of recurrent 
MI and cardiac deaths in subjects assigned to the active group compared to controls 
and the trial was stopped. An updated report with extended follow-up for 46 months 
confirmed the initial findings (117), however, few events occurred in both treatment 
arms and given the nature of the multicomponent intervention the observed lower rate 
of MI and cardiac death can not be specifically attributed to a higher ALA intake.  
In the double-blinded, more recent placebo-controlled Alpha-Omega-Trial (118), 
4,837 patients aged 60 to 80 years of age with a prior MI were randomly assigned to 
receive trial margarines providing either 2g ALA, 0.4g EPA+DHA or both, or placebo 
(margarine without n-3 supplementation) according to a parallel 2-by-2 factorial 
design. Those assigned to ALA supplementation were compared to subjects assigned 
to placebo and EPA+DHA rather than placebo alone. After 40 months of follow-up, 
a modest statistically non-significant lower rate of major cardiovascular events (HR: 
0.91, 95% CI: 0.78-1.05) including fatal and non-fatal cardiovascular events and 
cardiac interventions were observed in subjects assigned to ALA supplementation 
(319 events) compared to those assigned to placebo or EPA+DHA only (352 events) 
(118). In subgroup analyses, statistically non-significant lower rates of major 
cardiovascular events were observed in subjects below 70 years of age (HR: 0.83, 
95% CI: 0.67-1.03) and in women (HR: 0.73, 95% CI: 0.51-1.03) receiving 
supplementation with ALA compared to those receiving EPA+DHA supplementation 
and placebo. No associations were observed in males and subjects above 70 years of 
age (118). These subgroup analyses should, however, be interpreted with caution due 
to a limited number of events.  
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The large methodological heterogeneity in terms of study populations and designs, 
composition of supplementations, and trial duration makes comparison of study 
findings from these clinical supplementation trials difficult. Randomized controlled 
trials with hard endpoints are generally considered the gold standard of scientific 
evidence. However, in the context of nutritional research carefully conducted 
prospective observational studies may be more suited to answer questions on the role 
of dietary exposures in the general population on development of ASCVD because 
the etiologic period is long and large clinical supplemental trials are seldom feasible 
in a setting of primary prevention.   
 47 
CHAPTER 7. CONCLUSIONS AND 
PERSPECTIVES 
In this thesis associations between dietary intake of ALA and adipose tissue content 
of ALA and development of ASCVD including MI, ischemic stroke and PAD were 
investigated. We found that dietary intake of ALA was not consistently nor 
appreciably associated with the rate of incident MI, total ischemic stroke or ischemic 
strokes of presumed atherosclerotic origin or PAD. We did, however, find a 
statistically significant U-shaped association between the content of ALA in adipose 
tissue and the rate of ischemic stroke due to large artery atherosclerosis and 
indications of U-shaped pattern of associations between ALA content in adipose tissue 
and the rate of MI in women, total ischemic stroke and PAD.  
The observed U-shaped pattern of associations in analyses of adipose tissue content 
of ALA for these different atherosclerotic outcomes included in this thesis is not clear, 
but might impose that metabolic factors may be of importance for the association 
between ALA exposure and development of ASCVD. Thus, ALA may be influenced 
by several factors from intake to incorporation into adipose tissue including 
competition between PUFAs for metabolism and incorporation into adipose tissue and 
potential genetic differences in the shared enzymes responsible for PUFA synthesis. 
Therefore, further research on whether interplay between PUFAs and potential genetic 
differences in shared metabolic enzymes influence the associations between PUFA 
intake and development of ASCVD is warranted.  
Studies relying on self-reported intake may be limited by measurement error, which 
may reduce the possibility to detect true associations. In contrast, the content of ALA 
in human tissue such as adipose tissue can be assessed more precise and the content 
herein are considered an objective long-term biomarker of endogenous ALA 
exposure. However, the content of ALA in human tissue may be influenced by 
metabolism and intake of other fatty acids. Thus, both dietary and biomarker studies 
of ALA do have limitations, but the use of complementary estimates of exposure may 
contribute with valuable information and should be considered when possible in future 
studies. However, it should be emphasized that our estimates of exposure were 
indicators of an underlying dietary pattern. We described these dietary patterns using 
radar plots and found that our measures of exposures were indicators of complex 
underlying dietary patterns, which may differ by country and the population under 
study. Interestingly, ALA has been suggested to be an important part of the 
Mediterranean diet, which has been associated with a lower risk of major 
cardiovascular events (15). However, the protective effect on CVD provided by the 
Mediterranean diet may be attributable to a combination of several dietary factors 
acting in concert rather than a single component like ALA. Thus, it should be stressed 
that we did not evaluate the potential effect of a Mediterranean diet on ASCVD risk, 
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but the associations between estimates of ALA exposure representing indicators of 
underlying dietary patterns in relation to development of ASCVD. However, 
investigation of dietary patterns such as the Mediterranean diet in relation to 
development of ASCVD represent interesting areas for further research. Dietary 
pattern analyses may circumvent challenges in differentiating between individual and 
correlated dietary factors and may address the combined effect of dietary patterns on 
disease risk, which may be of great public health relevance. Further, the associations 
between PUFAs and ASCVD may depend on the nutrients used to replace them and 
substitution aspects of dietary factors in relation of ASCVD risk warrant further 
investigation.  
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ENGLISH SUMMARY 
Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of death 
globally. The plant-derived n-3 polyunsaturated fatty acid (PUFA), alpha-linolenic 
acid (ALA) has been associated with beneficial effects on atherosclerosis 
development, but previous investigations on hard vascular endpoints have shown 
inconsistent results. Further, most previous studies have focused on coronary heart 
disease, while the other major atherosclerotic diseases including ischemic stroke and 
PAD have been less studied.  
The objective of this thesis was to investigate the associations between the energy-
adjusted intake of ALA and adipose tissue content of ALA and the rate of myocardial 
infarction (MI), ischemic stroke and peripheral artery disease (PAD). We 
hypothesized that these estimates of ALA exposure were inversely associated with the 
rate of incident MI, ischemic stroke and PAD.   
This thesis was based on data from the Danish Diet, Cancer and Health cohort, which 
is a cohort of more than 57,000 middle-aged Danish men and women. Intake of ALA 
was assessed using a food frequency questionnaire. Adipose tissue content of ALA 
was determined by gas chromatography in all cases and a randomly drawn sub-cohort. 
All cases were identified by record linkage with nationwide Danish registers. The 
association between energy-adjusted ALA intake and the outcomes of interest were 
investigated using a traditional cohort design, whereas the association between 
adipose tissue content of ALA and outcomes were investigated using a case-cohort 
design. Hazard ratios obtained using Cox proportional hazard regression were used as 
measures of association.  
We found that dietary intake of ALA was not consistently nor appreciably associated 
with the rate of incident MI, total ischemic stroke or ischemic strokes of presumed 
atherosclerotic origin or PAD. In analyses of adipose tissue content of ALA, we 
observed indications of U-shaped pattern of associations between ALA content in 
adipose tissue and the rate of MI in women, total ischemic stroke and PAD, but these 
associations were not statistically significant. However, in analyses of ischemic stroke 
subtypes of atherosclerotic origin we observed a statistically significant U-shaped 
association between adipose tissue content of ALA and ischemic stroke due to large 
artery atherosclerosis, while no appreciable association was observed for ischemic 
strokes due to small-vessel occlusion. 
In conclusion, our studies did not lend support to our hypothesis that estimates of ALA 
exposure were inversely associated with the risk incident MI, ischemic strokes or 
PAD. Perspectives for further research on the association between ALA and ASCVD 
include investigations of the influence of potential interaction between ALA and the 
major n-6 PUFA linoleic acid on ASCVD risk and the importance of genetic 
differences in the shared metabolic enzymes important for PUFA metabolism on 
ASCVD risk warrant further investigation.  
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DANSK RESUME 
Aterosklerotisk kardiovaskulærsygdom er fortsat den primære årsag til død på 
verdensplan. Den plante-derivede n-3 polyumættede fedtsyre alpha-linolensyre 
(ALA) er blevet forbundet med gunstige effekter  som menes at reducere 
åreforkalkning, men tidligere studier med hårde vaskulære endepunkter har vist 
inkonsistente resultater. Ydermere har de fleste tidligere studier fokuseret på 
koronarkarsygdom, mens sammenhængen mellem ALA og iskæmisk slagtilfælde og 
perifer arteriesygdom kun i begrænset omfang er blevet undersøgt.  
Formålet med denne afhandling var at undersøge sammenhængen mellem det energi-
justerede indtag af ALA samt indholdet af ALA i fedtvæv og risikoen for udvikling 
af myokardieinfarkt, iskæmisk slagtilfælde og perifer arteriesygdom. Vores hypotese 
var at disse mål for eksponering af ALA var inverst forbundet med risikoen for 
udvikling af myokardieinfarkt (MI), iskæmisk slagtilfælde og perifer arteriesygdom.  
Denne afhandling er baseret på data fra den danske befolkningsundersøgelse Kost, 
Kræft og Helbred, som er en kohorte med mere end 57,000 midaldrende danske mænd 
og kvinder. Indtaget af ALA blev beregnet med udgangspunkt i et fødevare-
frekvensspørgeskema, mens indholdet af ALA i fedtvæv blev bestemt med 
udgangspunkt i gaskromatografi blandt alle cases og en vilkårligt udtrykket sub-
kohorte. Alle cases blev identificeret gennem nationale danske registre. 
Sammenhængen mellem det energi-justerede indtag af ALA og de tidligere beskrevne 
udfald blev undersøgt med udgangspunkt i et traditionelt kohortedesign, mens 
analyser baseret på indholdet af ALA i fedtvæv blev undersøgt baseret på et case-
kohortedesign. Hazard ratioer beregnet med udgangspunkt i Cox proportional hazard 
regression blev benyttet som associationsmål.  
Vi fandt ingen sammenhæng mellem indtag af ALA og risikoen for udvikling af MI, 
iskæmisk slagtilfælde og perifer arteriesygdom. I analyser af indholdet af ALA i 
fedtvæv fandt vi indikationer på en U-formet sammenhæng mellem indholdet af ALA 
i fedtvæv og risikoen for MI blandt kvinder, total iskæmisk slagtilfælde og perifer 
arteriesygdom. I analyser af subtyper af iskæmisk slagtilfælde fandt vi en statistisk 
signifikant U-formet sammenhæng mellem indholdet af ALA i fedtvæv og risikoen 
for iskæmisk slagtilfælde forårsaget af storkarssygdom, mens ingen betydende 
sammenhæng blev fundet for iskæmisk slagtilfælde forårsaget af småkarssygdom. 
Disse studier bekræfter således ikke vores hypotese om, at indtag eller 
koncentrationen af ALA i fedtvæv er inverst associeret med risikoen for udvikling af 
MI, iskæmisk slagtilfælde eller perifer arteriesygdom. Perspektiver for videre 
forskning i sammenhængen mellem ALA og aterosklerotisk kardiovaskulærsygdom 
inkluderer undersøgelser af betydningen af interaktion mellem ALA og den primære 
n-6 polyumættede fedtsyre, linolsyre, samt undersøgelser af betydningen af mulige 
genetiske forskelle i fælles enzymer involveret i omdannelsen af disse fedtsyrer.  
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Appendix Figure 1. Forest plot of the associations between quintiles of energy-
adjusted ALA intake and the rate of MI, ischemic stroke and PAD. The analyses were 
adjusted for established risk factors and potential dietary risk factors (model 3).  
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